Thomas Lampron formally announced on LinkedIn this week that he is 'thrilled to join the powerhouse team at Revolution Medicines' as VP, global commercial pancreas lead, ending a 13-year career with Merck.
June 5, 2026 07:00 AM EDT
Peer Review
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec
Alex Hoffman
Copy Chief and News Editor
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
What RevMed's pancreatic cancer drug meant for one patient
Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Evotec Appoints Rui Wang as Head of Global In Silico and AI
Will Makary's FDA voucher program survive?
Radiopharmaceutical shows promise in post-Pluvicto setting
Novo Nordisk's global research head Jacob Sten Petersen discusses post-reorganization R&D strategy, pipeline diversification…
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by…
Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Jorgensen, who joined in 2017, has had the shortest tenure of all. Danish couple August and Marie Krogh founded Nordsik…
